Taltz® Receives Pediatric Indication

Every year, roughly 20,000 children under 10 years of age are diagnosed with psoriasis.[1] Despite that, there remains an unmet need for pediatric psoriasis treatments. However, a new biologic treatment option is on the horizon. On March 30, 2020, the U.S. Food and Drug Administration approved the use of Taltz® (ixekizumab) for use in pediatric patients, six years of age or older, with moderate to severe plaque psoriasis, who are candidates for systemic therapy or phototherapy.

Taltz®, manufactured by Eli Lilly, acts by binding with a substance involved in normal inflammatory and immune responses (interleukin 17A cytokine), which is produced by T helper 17 cells (Th17, a type of immune cell), and preventing the interaction with its receptor. This action helps to stop the release of substances which can cause inflammation.[2]

“One percent of all children have psoriasis and up to about 1/4 of these are moderate to severe and require more than topical medications. Research has shown that the Th17 pathway is critical to psoriasis pathogenesis, and the Th17 pathway inhibitors have been superior in efficacy for skin disease to the TNF inhibitors in adults. This is the first study showing the efficacy of a Th17 inhibitor in the pediatric population, and indicated outstanding results for pediatric patients with moderate to severe psoriasis,” said Amy Paller, M.D., the chair of the dermatology department at Northwestern University.

In the phase 3 study, the patients, aged 6 years to younger than 18 years, were randomized to receive Taltz® (dosing was 20, 40 or 80 mg based on weight) or placebo. After 12 weeks, 89 percent of patients treated with Taltz® achieved PASI 75 (Psoriasis Area and Severity Index score) compared to 25 percent for patients who were treated with placebo. Additionally, 81 percent of patients achieved sPGA (static Physician's Global Assessment) 0,1 compared to 11 percent for patients treated with placebo.[2] 

The approval for ixekizumab in the U.S. now provides the third approved biologic for pediatrics and only the fourth for children under the age of 12. In addition, having the backing of a large clinical trial, this helps tremendously knowing appropriate dosing guidelines. It's very exciting, as a pediatric dermatologist, to know that I may have access to a medication for my patients that can get them clear and works quickly as well as an option for patients that may have failed other treatment modalities. I hope this is a sign of further expansion of our pediatric psoriasis treatment options,” said Lara Wine Lee, M.D., a pediatric dermatologist at the Medical University of South Carolina in Charleston.

The Eli Lilly drug was previously approved for the treatment of adults with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy, as well as adults with active psoriatic arthritis and active ankylosing spondylitis.[2]

The National Psoriasis Foundation (NPF) is proud to be a driving force in psoriatic disease research and patient advocacy to aid in improving the health of those living with psoriatic disease. In 2016, NPF rallied patients to be heard at the FDA’s Patient-Focused Drug Development Initiative meeting about psoriasis. Over 200 people responded to the call and shared stories about the impact psoriasis had on their lives, the significant burden on daily life and about their experiences with various treatment options. One of the many reasons this meeting was exceptional was because it highlighted the unmet medical need for more treatments for pediatric patients living with psoriasis, which highlights why this new indication is so important.

Have questions about psoriatic disease treatment options? NPF’s Patient Navigation Center is available to anyone impacted by psoriatic disease to help answer questions and find solutions so patients can live their healthiest life.

Disclosure: Dr. Wine Lee was an investigator and member of the advisory board for ixekizumab for pediatric psoriasis. She was paid for these activities.   


Driving discovery, creating community

For more than 50 years, we’ve been driving efforts to cure psoriatic disease and improve the lives of those affected. But there’s still plenty to do! Learn how you can help our advocacy team shape the laws and policies that affect people with psoriasis and psoriatic arthritis – in your state and across the country. Help us raise funds to support research by joining Team NPF, where you can walk, run, cycle, play bingo or create your own fundraising event. If you or someone you love needs free, personalized support for living a healthier life with psoriatic disease, contact our Patient Navigation Center. And keep the National Psoriasis Foundation going strong by making a donation today. Together, we will find a cure.

Recent Advance Posts

research into new drug treatments in pipeline for psoriasis
More biologics, an oral medication and a topical draw interest from top...
Offering “byte”-sized medical news updates for health care providers.
Psoriasis in your fingernails and toenails can be a sign of troubles to come.
man scalp psoriasis happy with treatment
FDA Approves Otezla® for the Treatment of Scalp Psoriasis
FDA Approves Taltz® for the Treatment of Pediatric Patients with Moderate to...
NPF wants to help medical pros and their patients with the Biologic Fulfillment...
A woman with psoriasis and psoriatic arthritis charts a new course in her...
Dr. Ronald Prussick
A chance meeting with an inspiring mentor channels a promising physician into a...
hand with arthritis on mouse beside keyboard
We take many common movements and activities for granted – until they become...